ReviewSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2017
Patient reported outcome measures (PROMs) in sarcoidosis.
Review in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Trial
- Feasibility of investigating methylphenidate for the treatment of sarcoidosis-associated fatigue (the FaST-MP study): a double-blind, parallel-arm randomised feasibility trial.BMJ open respiratory research · 2021Trial
- Quality of Life in Sarcoidosis.Diagnostics (Basel, Switzerland) · 2026Review
- Radiomic profiling of chest CT in a cohort of sarcoidosis cases.Scientific reports · 2026Article
- Neuropsychiatric manifestations of sarcoidosis.Annals of medicine · 2025Review
- Longitudinal validation of King's Sarcoidosis Questionnaire in a prospective cohort with mild sarcoidosis.ERJ open research · 2024Article
- Risk of depression and anxiety in 7.302 patients with sarcoidosis: a nationwide cohort study.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2024Article
- The Symptoms of Pulmonary Sarcoidosis.Journal of clinical medicine · 2023Review
- Validity and Reliability of the Fatigue Severity Scale in a Real-World Interstitial Lung Disease Cohort.American journal of respiratory and critical care medicine · 2023Article
- Health-related quality of life in cardiac sarcoidosis: a systematic review.European heart journal open · 2023Review
- Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement.American journal of respiratory and critical care medicine · 2021Article
- Scout - sarcoidosis outcomes taskforce. A systematic review of outcomes to inform the development of a core outcome set for pulmonary sarcoidosis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2021Article
- Comprehensive Care for Patients with Sarcoidosis.Journal of clinical medicine · 2020Review
- Predictors of cough-specific and generic quality of life in sarcoidosis patients.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2020Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with sarcoidosis present with a variety of symptoms which may impair many aspects of physical and mental well-being. Traditionally, clinicians have been concerned with physical health aspects of sarcoidosis, assessing disease activity and severity with radiological imaging, pulmonary function and blood tests. However, the most reported symptom of sarcoidosis patients, fatigue, has been shown not to correlate with the most commonly used parameters for monitoring disease activity. Studies have shown poor agreement between physicians and patients in assessing sarcoidosis symptoms. This underlines the importance of patient reported outcomes (PROs) in addition to traditional outcomes in order to provide a complete evaluation of the effects of interventions in clinical trials and everyday clinical assessment of sarcoidosis. We have undertaken a systematic review to identify and provide an overview of PRO concepts used in sarcoidosis assessment the past 20 years and to evaluate the tools used for measuring these concepts, called patient reported outcome measures (PROMs). Various PROMs have been used. By categorizing these PROMs according to outcome we identified the key PRO concepts for sarcoidosis to be Health Status and Quality of Life, Dyspnea, Fatigue, Depression, Anxiety and Stress and Miscellaneous. There is no perfect sarcoidosis-specific PROM to cover all concepts and future intervention studies should therefore contain multiple complementary questionnaires. Based on our findings we recommend the Fatigue Assessment Scale (FAS) for assessing fatigue. Dyspnea scores should be chosen based on their purpose; more research is needed to examine their validity in sarcoidosis. The Modified Medical Research Council Dyspnea Scale (MRC) can be used to screen for dyspnea and the Baseline Dyspnea Index (BDI) to detect changes in dyspnea. We recommend The World Health Organization Quality of Life assessment instrument (WHOQOL-100) for assessing quality of life, although a shorter questionnaire would be preferable. For assessing health status we recommend the Sarcoidosis Assessment Tool (SAT), and have great expectations for this new and promising assessment tool. Supplementary to the WASOG meeting of 2011's recommendation on assessing QoL, we recommend incorporating fatigue, dyspnea and HS assessment in clinical trials and everyday clinical assessment of sarcoidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.